Loren Data's SAM Daily™

FBO DAILY ISSUE OF JUNE 20, 2009 FBO #2763
SOURCES SOUGHT

65 -- Hand Sanitizers - Waterless Products for Standardization

Notice Date

6/18/2009
 

Notice Type

Sources Sought
 

NAICS

423450 — Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
 

Contracting Office

Department of the Army, U.S. Army Medical Command, European Regional Contracting Office, European Regional Contracting Office, ATTN:MCAA E, Building 3705, Landstuhl, Germany APO, AE 09180
 

ZIP Code

09180
 

Solicitation Number

W9114F-09-T-9977
 

Response Due

7/9/2009
 

Archive Date

9/7/2009
 

Point of Contact

Gina A Barto, 011496371866021<br />
 

E-Mail Address

European Regional Contracting Office
(gina.p.alfonso@us.army.mil)
 

Small Business Set-Aside

N/A
 

Description

A.General Information The Tri-Service Standardization Europe Region announces the standardization initiative for Hand Sanitizers-Waterless for its 44 Army, Navy, and US Air Force medical treatment facilities (MTF) in Germany, Italy, Portugal, Spain, Turkey, and the United Kingdom. Standardization for this product line, Hand Sanitizers-Waterless, represents a previously standardized product line initiative for the Europe Region. The Europe Region originally completed this product line for standardization in 2004 and it expires November 30, 2009. The current vendor chosen for this product line is GOJO Industries. This product line includes but is not limited to Hand Sanitizers-Waterless in both liquid/gel and foam formulas containing a moisturizer with an alcohol content of between 60%-95% [per the Centers for Disease Control and Prevention (CDC), Guideline for Hand Hygiene in Health-Care Settings, October 2002 in 2, 4-7, and 32 ounce containers. 1.The Hand Sanitizers-Waterless samples: 6 of each size as stated below per each of the six (6) MTFs as follows. The below formulas, liquid/gel and foam, must contain a moisturizer. a.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Liquid/Gel Formula b.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Foam Formula 2.For each category of product sample specified above the vendor must provide the appropriate product dispensers. Product dispensers suitable for desk/counter-top use are preferred, but product dispensers for temporary wall mounting will be accepted. This RIA initiative will be a Two Phase RIA Process: Vendor(s) who meet the technical/company criteria in Phase I will be invited to advance and participate in Phase II where pricing will be required for submittal along with no charge product literature and samples. Vendors must provide a complete list of items supplied (catalog, etc.) and product literature in response to this RFQ. Vendors are required to supply all items listed in all sizes and styles listed. Vendors who do not have a complete product line, as detailed below in usage items, will be disqualified in Phase I. The primary objective of this standardization initiative is to standardize the quality of health care across the Europe Region and to achieve a best value determination for Hand Sanitizers-Waterless. The outcome of this review represents the clinically preferred product and/or source at the best possible price. The devices selected will be used by the Army, Navy, and Air Force to deliver patient care at operational CENTCOM facilities in the region and at MTFs in EUCOM. It is expected that 80% of the total requirements of the MTFs of the Europe Region will be purchased through the resulting RIA. The standardized products will be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program via USAMMCE. The major facilities in the Europe Region include but are not limited to Landstuhl Regional Medical Center, U. S. Army Medical Activity Heidelberg, U. S. Army Medical Activity Bavaria, U. S. Army Health Center - Vicenza, 48th Medical Group RAF Lakenheath, 31st Medical Group Aviano, 52nd Medical Group Spangdahlem, 86th Medical Group Ramstein, 39th Medical Group Incirlik, 65th Medical Group Azores, U. S. Naval Hospital Naples, U. S. Naval Hospital Rota, U. S. Naval Hospital Sigonella, U. S. Army 30th Medical Command, and U. S. Army Central Command. This standardization action is part of the Medical/Surgical Prime Vendor program executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the Prime Vendors for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow Prime Vendors to distribute their items. This Request for Quotes (RFQ) will result in Regional Incentive Agreements that supplement the Prime Vendor Program. The RFQ will not result in a contract award. For additional information regarding DSCPs Prime vendor program, please access their web site at https://dmmonline.dscp.dla.mil. The resulting Regional Incentive Agreement (RIA) will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month option periods for a maximum of 5 years. The anticipated selection date is November 2009. The evaluation will be based on clinical, technical, and pricing factors. The Technical/Company and Clinical/Performance evaluation factors, when combined, are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determined utilizing best value, lowest overall cost factors, with pricing being least important. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Europe Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of Military Treatment Facility (MTF) preference and product availability. Point of Contact (POC) is Mr. Robert Halliday, phone: 011-49-6221-172108, and e-mail robert.halliday@us.army.mil B.Products & Performance Required 1.The Europe Region is seeking product line items in the category of Hand Sanitizers-Waterless, which at a minimum includes the product lines below. Within the Europe Region, this product line has an estimated annual dollar requirement of $247,687. This forecast is based on historical prime vendor sales during a recent 12-month period. The top high volume usage lines for this project include: At a minimum, a complete product line includes but is not limited to Hand Sanitizers-Waterless in both liquid/gel and foam formulas containing a moisturizer with an alcohol content of between 60%-95% [per the Centers for Disease Control and Prevention (CDC), Guideline for Hand Hygiene in Health-Care Settings, October 2002 in 2, 4-7, and 32 ounce containers. a.The Hand Sanitizers-Waterless samples: 6 of each size as stated below per each of the six (6) MTFs as follows. The below formulas, liquid/gel and foam, must contain a moisturizer. b.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Liquid/Gel Formula c.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Foam Formula d.For each category of product sample specified above the vendor must provide the appropriate product dispensers. Product dispensers suitable for desk/counter-top use are preferred, but product dispensers for temporary wall mounting will be accepted. 2.Vendors must provide a complete list of items supplied (catalog, etc.) and product literature (including MSDS information) in response to this RFQ. Vendors are required to supply all items (sizes are approximate) listed above. Vendors who do not meet this criterion will be disqualified in Phase I. 3.At the request of the Europe Region MTFs, vendors will provide on-site support and in-servicing during implementation, educational resources and tools for clinical use of the product, conversion information, prime vendor order numbers, MSDS information, and itemization of the brands, types and packaging information of the products supplied by the vendor. Vendors who do not meet this criterion will be disqualified in Phase I. C.Instructions to Vendors DAPA holders interested in participating in this standardization initiative must E-mail your response to robert.halliday@us.army.mil and provide: (1) Company name and address, (2) point of contact information (Name and Phone Number, Fax Number, and E-mail Address), (3) the company DAPA number, and (4) the company detailed responses to the questions under Technical/Company Criteria below. All e-mail communication between vendors and the Europe Region must be digitally signed. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) must be digitally signed as well. Submissions must be received by close of business (COB) on the specified closing date of this RFQ. Vendors that fail to meet this submittal deadline will be disqualified from participating. This process will include vendor requirements for providing electronic responses to technical criteria, no charge literature for clinical evaluation, and submission of electronic best price quotes. Due to the potential for e-mail to be lost in transmission from network security, etc., vendors are strongly encouraged to confirm with the Europe Regional POC stated above their initial submission, best price submissions, and literature or other requested information has actually arrived at the Europe Regional Tri-Service Business Office (TRBO) via e-mail. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Vendors that do not meet the deadline of COB on the date listed for closing (per the FBO RFQ); will be disqualified from further consideration in the standardization initiative. All e-mail communications between vendors and the Europe Region must be digitally signed by the issuer. D.Evaluation Criteria The Europe Tri-Service Product Review Board (TPRB) is the governing board of the standardization process. This board includes clinicians and logisticians from all of the MTFs within the Europe Region. They are the decision makers for this initiative. The Europe Region intends to evaluate price quotes and select a vendor or vendors, without discussions. Vendor quotes should contain the vendors best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendors best responses to all technical and/or company questions listed in this announcement. Vendor quotes should contain the vendors best tiered-pricing discounts off of the vendors DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Europe Region). (Note: vendors that fail to submit a discount from DAPA will be disqualified. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. Vendors shall not quote FSS prices as the discounted price for purposes of this standardization initiative.) Additionally, the Europe Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down selection is made during the evaluation process, the Europe Region may limit the number of quotes to the greatest number that will permit an efficient competition among vendors. Phase I - Technical/Company Evaluation Process Interested vendors are to respond to this FBO announcement by e-mailing their detailed responses and required documentation to robert.halliday@us.army.mil by the required response date. Vendors are required to meet/provide responses to the technical/company criteria stated below. All technical/company criteria are weighted equally. The responses will be reviewed under the purview of the Europe TPRB and the Europe Clinical Product Team (CPT) to determine acceptability of each vendor. After review of the technical/company criteria, those vendors who meet these criteria will be qualified/invited to participate in the clinical/performance evaluation process as well as the price analysis process and will be requested to submit their best product/price discount quotes via an e-mail communication with each vendor. 1.In general, acceptability for purposes of evaluation of technical/company criteria is defined as follows: a.Based on the vendors responses, the evaluators have reasonable confidence that the line or products and/or services submitted meet the medical standards of care of the community applicable to such products or services. b.The vendors information provided is factually correct. Any misrepresentation of information will disqualify the vendor from further consideration. c.Each technical/company criteria below provides additional, more specific definition of technical acceptability. This specific standard for technical acceptability will be set forth with the individual criterion. d.The vendors who meet the following technical /company criteria will be qualified/invited to participate in the clinical/performance evaluation process via an e-mail communication with each vendor. e.Vendors must provide a complete product line of Hand Sanitizers-Waterless products. A complete line of product is defined as the MTFs requirements for usage items in the product line. Usage items are defined for this report as items used in the Europe Theater within a 12-month period. During the pre-source selection procedures, the Europe CPT validated/approved the equally weighted company/technical criteria outlined below. (Note the eleven (11) criteria below must be answered with the vendors initial submittal by the response date stated in the FBO announcement). Technical/Company Criteria: 1.Vendors must provide a complete product line of Hand Sanitizers-Waterless products. A complete line of product is defined as the MTFs requirements for usage items in the product line. Usage items are defined for this report as items used in the Europe Theater within a twelve month period. a.At a minimum, a complete product line includes but is not limited to Hand Sanitizers-Waterless in both liquid/gel and foam formulas containing a moisturizer with an alcohol content of between 60%-95% [per the Centers for Disease Control and Prevention (CDC), Guideline for Hand Hygiene in Health-Care Settings, October 2002 in 2, 4-7, and 32 ounce containers. b.The Hand Sanitizers-Waterless samples: 6 of each size as stated below per each of the six (6) MTFs as follows. The below formulas, liquid/gel and foam, must contain a moisturizer. 1)Multi-Use (minimum 9 oz. each) Hand Sanitizer - Liquid/Gel Formula 2)Multi-Use (minimum 9 oz. each) Hand Sanitizer - Foam Formula c.For each category of product sample specified above the vendor must provide the appropriate product dispensers. Product dispensers suitable for desk/counter-top use are preferred, but product dispensers for temporary wall mounting will be accepted d. Vendors must provide a complete list of items supplied (catalog, etc.) and product literature (including MSDS information) in response to this RFQ. Vendors are required to supply all items (sizes are approximate) listed above. Vendors who do not have a complete product line as listed above will be disqualified in Phase I. 2.Vendors must have a Distribution and Pricing Agreement (DAPA) for Hand Sanitizers-Waterless with Defense Supply Center Philadelphia (DSCP) or be in the process of applying for a DAPA number for the Hand Sanitizers-Waterless product line. Provide the DAPA number or proof of the application process in progress in response to this RFQ. NOTE: Vendors that fail to have a DAPA will be disqualified in Phase I. Your DAPA number is: __________________. 3.Vendors must have a separate agreement with the Prime Vendor (PV), Owens & Minor, for the Hand Sanitizers-Waterless product line distribution in the Europe Region. Vendor must provide the four digit Owens & Minor Code with their initial submittal. (Note a vendor whose products are not available through the Europe Regional PV (Owens & Minor) will be disqualified in Phase I.) Your Owens & Minor Code number is: __________________. 4.Vendors must submit discounts off DAPA for all products included in this standardization initiative. Note: vendors that fail to submit a discount from DAPA will be disqualified. Where lower uncommitted Federal Supply Schedule (FSS) prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. Vendors shall not quote FSS prices as the discounted price for purposes of this standardization initiative. Vendors who do not provide discounts off DAPA for all products in Phase II will be disqualified. 5.Vendors must have a vendor representative for the Europe Region Medical Treatment Facilities to provide sufficient product implementation services and customer servicing to the multi-service regional facilities. Provide contact information, i.e., name, address, phone number, and e-mail address in response to this RFQ. Vendors must identify company resources (on-site visits, on-line support, and different portable media) for such requirements in response to this RFQ. Provide electronic literature, if available, describing this support. Vendors who do not meet this criterion will be disqualified in Phase I. 6.Vendor must provide electronic and hard copy proposed pricing and a competitive product cross-reference in electronic Microsoft Excel format upon request. Vendors who do not meet this criterion will be disqualified in Phase I. 7.Vendors must indicate that they agree to ship samples necessary for evaluation to the Europe Region TRBO by close of business (COB) within 14 calendar days of request via United States Postal Service (USPS) eliminating delays that occur with Europes Custom Offices. Proof of vendor shipment (copy of the PS Form 2976-A with stamped date) via USPS prior to the established deadline must be scanned and sent via digitally signed e-mail to the Europe Region TRBO. Provide acknowledgement of this requirement in response to this RFQ. Vendors who do not meet this criterion will be disqualified in Phase I. 8.Vendors must provide latex-free product accessories/packaging in response to this RFQ. Vendors who do not meet this criterion will be eliminated in Phase I. 9.Vendors must provide products in individual/personal-sized packaging, and must provide multi-use dispensers that provide a pre-measured amount with each use. All dispensers must be clearly labeled as to contents and must include manufacturing lot number and must include expiration date as appropriate. Vendors who do not meet this criterion will be eliminated in Phase I. 10.The vendors products must not contain substances that compromise the integrity of latex medical gloves (for example, petrolatum, lanolin, mineral oil, or similar substances). Vendors who do not meet this criterion will be eliminated in Phase I. 11.Vendors must provide only the following no cost product samples for clinical/performance evaluation (unused samples will not be returned). Vendors who do not meet this criterion will be disqualified in Phase I. a.The Hand Sanitizers-Waterless samples: 6 of each size as stated below per each of the six (6) MTFs as follows. The below formulas, liquid/gel and foam, must contain a moisturizer. c.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Liquid/Gel Formula d.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Foam Formula b.For each category of product sample specified above the vendor must provide the appropriate product dispensers. Product dispensers suitable for desk/counter-top use are preferred, but product dispensers for temporary wall mounting will be accepted. c.Samples are to be shipped to the Europe Region TRBO. The Europe Region TRBO requests sample orders be separated by MTF. The Europe Region TRBO will have the responsibility of forwarding the samples to the participating MTFs. Vendors are not allowed to send any other product samples sets or materials other than what the Europe CPT has requested. Failure to abide by this request will disqualify the vendor from further consideration in this standardization process. Phase II - Clinical/Performance Evaluation Process and Pricing Analysis Clinical Evaluation Process In the pre-source selection procedures above, the Europe CPT determined/approved the product samples sets are required for the evaluation in a clinical (patient care) setting. Requested samples will only include high-volume products. Based on this determination, the following procedures will apply. 1.To avoid shipping delays caused by Europes Customs Offices, the Europe Region TRBO office requires sample sets from each qualifying vendor to be sent directly to the Europe Region TRBO via e-mail address robert.halliday@us.army.mil or USPS to the following APO address: Commander, Europe Regional Medical Command Attn: G-4 Tri-Service Standardization Mr. Robert Halliday, (011-49-6221-172108) CMR 442 APO AE 09042 2.Vendors will be given 14 calendar days from the issue of the notice to ship product samples / literature for the clinical evaluation at Phase II. Vendors who do not meet the deadline for the shipment of samples by COB on the 14th calendar day after the issue date of the notice to supply samples will be disqualified from the standardization process. NOTE: All vendors must send Europe Region TRBO POC verification regarding the date of shipment from the vendor and the anticipated delivery date via e-mail digitally signed. Verification of shipment is defined as sending the Europe Region TRBO a copy of the USPS PS form 2976-A customs form. The PS form 2976-A will have a stamped date the package was accepted by USPS. Vendors whose packages have a stamped date after the established notification to ship deadline date will be disqualified from this standardization process. 3.Vendor will provide, the only following no cost product samples for clinical/performance evaluation (unused samples will not be returned). a.The Hand Sanitizers-Waterless samples: 6 of each size as stated below per each of the six (6) MTFs as follows. The below formulas, liquid/gel and foam, must contain a moisturizer. e.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Liquid/Gel Formula f.Multi-Use (minimum 9 oz. each) Hand Sanitizer - Foam Formula b.For each category of product sample specified above the vendor must provide the appropriate product dispensers. Product dispensers suitable for desk/counter-top use are preferred, but product dispensers for temporary wall mounting will be accepted. c.Samples are to be shipped to the Europe Region TRBO. The Europe Region TRBO requests sample orders be separated by MTF. The Europe Region TRBO will have the responsibility of forwarding the samples to the participating MTFs. Vendors are not allowed to send any other product samples sets or materials other than what the Europe CPT has requested. Failure to abide by this request will disqualify the vendor from further consideration in this standardization process. 4.The specific Rules of Engagement for this standardization initiative. a.Vendors will only provide sample products of the items that are requested and being evaluated. Vendors that bring in other product samples or literature on items that are not part of the evaluation process will be disqualified from the evaluation process. b.Vendors presence will not be required for in-servicing prior to or during the evaluations. c.Vendors will not be allowed to be present during the actual evaluation process of their products or their competitors products. d.Vendors will not be allowed to speak to any hospital staff member regarding the product evaluation, product pricing or pricerelated factors. Vendors that speak to hospital staff members regarding the product evaluation; pricing or pricerelated factor will be disqualified from this evaluation process. e.Each of the six(6) MTFs will evaluate a vendors product line five (5) different times, for three (3) 8 to 12 hour days (this involves numerous hand washing episodes) then breaking for two days before a different competitors product is evaluated in a clinical (patient care) setting. The MTFs will complete this evaluation process within 30 days. 5.The Europe CPT will evaluate each vendors sample sets against the clinical/performance criteria in a clinical (patient care) setting. 6.All clinical/performance criteria are weighted equally: 7.The evaluation responses will be in a Likert scale format with a 1-5 scoring range. The scale descriptors are: one (1) not acceptable, two (2) minimally acceptable, three (3) acceptable, four (4) more acceptable, and five (5) highly acceptable. The Europe CPT has established a target threshold of 3.0 for the clinical acceptability of products for standardization. The Europe CPT will determine the actual acceptability threshold for this standardization initiative at or near 3.0 depending on the location of any break in vendors average scores. In addition, the Europe CPT may consider how closely scores are clustered near the Acceptability Target Threshold of 3.0, in determining the actual acceptability threshold. Vendors scoring below the actual acceptability threshold will be determined to be clinically unacceptable, and be disqualified from further consideration for this standardization initiative. Vendors that have been disqualified will be notified in writing at the conclusion of the evaluation process (DSCP approval). 8.To determine acceptability, a Europe CPT comprised of medical professionals from the MTFs will evaluate the products based on the evaluation criterion stated below. It is intended that clinical evaluations shall be conducted in a clinical (patient care) setting. 9.Clinical/performance evaluations will be tabulated by the Europe Region TRBO, and results will be forwarded to the Europe CPT for final review. Clinical/Performance Criteria: During the pre-source selection procedures, the CPT evaluated products based on the equally weighted clinical/performance criteria outlined below. The product line will be evaluated by using a combination, not all, of the approved clinical/performance criteria as above. The evaluation forms will use the following above clinical/performance criteria. 1.(Staff Compliance/Efficiency of Care/Staff-Patient Safety/JC NPSG07.01.01-Reduce the risk of health care associated infections) The hand sanitizer product dispenses pre-measured amount effortlessly without repeated attempts and/or without clogging and/or dripping from the dispensing nozzle. a.Effortless dispensing is a key component in staff compliance and time efficiency during patient care; no-drip dispensing prevents a safety risk from wet floors/counters. b.Evaluator will observe dispensers for barriers to ease of dispensing such as repeated attempts, clogging, and/or dripping leading to an insufficient amount for effective cleansing. 2.(Staff Compliance/Staff-Patient Safety) The hand sanitizer product absorbs easily and quickly. a.Easy and quick absorption is a key component in staff compliance and time efficiency during patient care; quick absorption prevents slippery skin surfaces which place staff/patients at risk for mishaps/injury. b.Evaluator will observe for consistent absorption and drying time less than 30 seconds. 3.(Staff Compliance/Infection Control/Staff Comfort) The hand sanitizer product leaves the skin feeling smooth, soft, and non-irritated (not dry, cracked, chafed or irritated). c.Dry, cracked, chafed, and/or irritated skin is a deterrent to staff compliance; dry, cracked, chafed, and/or irritated skin is vulnerable to infection. d.Evaluator will observe for dry, cracked, chafed, and/or irritated skin. 4. (Staff Compliance/Infection Control) The hand sanitizer product does not leave a greasy/oily and/or sticky/tacky residue/residue build-up on skin after absorption. e.Residue/residue build-up on skin after absorption may attract environmental microbes/pathogens placing staff/patients at risk for infection. f.Evaluator will observe for greasy/oily and/or sticky/tacky residue/residue build-up on skin. 5.(Staff Compliance/Staff-Patient Comfort) The hand sanitizer product scent/odor is not offensive during dispensing and/or after absorption. g.Offensive scent/odor may cause allergic/sensitivity response in staff and/or patients. h.Evaluator will observe for offensive scent/odor and/or lingering offensive scent/odor. 6.(Staff Compliance/Efficiency of Care) The hand sanitizer product does not interfere with donning or removal of medical gloves (exam or surgical gloves). a.Interference with donning/removal of medical gloves is a deterrent to the use of Hand Sanitizers and/or the use of medical gloves as personal protective equipment during patient care. b.After dispensing product and allowing absorb or dry on the skin, evaluator will don and remove medical gloves (exam or surgical gloves) and observe for ease of donning/removal of gloves. Pricing Analysis Process 1.Upon completion of Phase I Technical/Company Criteria Evaluation, vendors who are selected to progress to clinical/performance evaluations will be requested to provide their best product and price discount quotes concurrent with product samples being requested. Vendors will be given 14 calendar days from the date of pricing requests, to submit RIA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the Europe Region. Pricing must be received at the Europe Region TRBO by COB, fourteen (14) calendar days after the issue date of the vendor notice to submit best product and price quotes. The Europe Region intends to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendors best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendors best tiered-pricing discounts off of the vendors DAPA pricing (based on committed volume of 80% of the total requirements of the Europe MTFs). a.The Technical/Company and Clinical/Performance evaluation factors, when combined, are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determined utilizing best value, lowest overall cost factors, with pricing being least important. Pricing will be evaluated based on best value to the government and will be based on a committed volume for a two year period with three (3) one-year option periods. b.Vendors will forward pricing to the Europe Regional TRBO, and the Europe Regional TRBO will prepare a pricing analysis to be reviewed by the Europe TPRB. The Europe TPRB will select the vendor giving the best overall value both clinically and financially for the Europe Region. 2.The following elements will be considered in the pricing analysis and are listed in order of importance: a.Impact of RIA prices on the Europe Region. (Post-Standardization Costs). This represents the new estimated annual cost or the total cost post standardization and includes the vendors products, and the products that could not be matched. It reflects the amount the Europe Region would pay the vendor using the RIA pricing. This is the most important pricing element. b.Impact of Unmatched Lines. The unmatched lines make it difficult to compare the prices of the various vendors, because the evaluator cannot compare similar product lines for each vendor. Those items that are considered in the high usage category will have a higher impact to the Europe Region for the unmatched product line and the end post-standardization costs. c.Potential Cost Avoidance. Cost avoidance is calculated by subtracting the RIA price from the Distribution and Pricing Agreement (DAPA) price and multiplying by 12-months of usage. This is included as a reporting metric. d.Consideration of SKUs by each vendor. The Europe Region intends to reduce the number of SKUs that must be handled per period. Vendors that can supply the complete range of clinically-required product, without unnecessary numbers of SKUs for minimally-differentiated products, will be more likely to provide the best-value solution for the Government in this standardization initiative. 3.The Europe Region reserves the right to conduct discussions and request revised quotes, if determined necessary. The Europe Region reserves the right to limit the number of quotes to the greatest number that will permit an efficient competition among vendors. The Europe Region reserves the right to make a down-selection during the evaluation process based on considerations of efficient competition.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/USA/MEDCOM/DADA19/W9114F-09-T-9977/listing.html)
 

Place of Performance

Address: Europe Tri-Service Regional Business Office (TRBO) CMR 442 ATTN:G-4 Tri-Service Standardization APO AE<br />

Zip Code: 09042<br />
 

Record

SN01850000-W 20090620/090619000458-1452d4c54949866f700b54040ce30d07 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |